PRADAXA BLEEDING LAWSUITS UPDATE JULY 2012

PRADAXA BLEEDING LAWSUITS UPDATE JULY 2012 -
LEGAL CASES CONSOLIDATED IN MULTI DISTRICT LITIGATION

PRADAXA (DABIGATRAN ETEXILATE) BLEEDING LAWSUITS OVER BLOOD THINNER MOUNT.

As anticipated, mounting lawsuits against the manufacturer of PRADAXA (DABIGATRAN ETEXILATE), BOEHRINGER INGELHEIM, have been consolidated into a coordinated Multi-District Litigation (MDL). This will facilitate National litigation being filed in at one centralized location within the Federal court system. It is possible that similar State coordinated proceedings will be organized as PRADAXA BLEEDING cases continue to be screened and filed.

As noted below, PRADAXA (DABIGATRAN ETEXILATE) is a fairly new anti-coagulant that was celebrated as an alternative to treatment with COUMADIN or WARFARIN. In other words, it was marketed and packaged to providers/prescribers, as a new and improved way to treat patients in need of anti-coagulant therapy. However, unlike COUMADIN or WARFARIN, which have over 50 years of studies and practical use associated with the product, PRADAXA (DABIGATRAN ETEXILATE) has only been approved for use in the United States since October 2010. In this short period of time, the effects of PRADAXA BLOOD and adverse bleeding events have raised International concerns. In the United States, the ISMP has noted that the blood thinner has been linked to a number of deaths and become the most widely reported drug in association with adverse event reports to the U.S. Food & Drug Administration.

ISMP QuarterWatch Affirms PRADAXA concerns in 2012 based upon PRADAXA BLEEDING DEATHS..

The number of pending lawsuits against BOEHRINGER INGELHEIM is expected to grow through 2012. Sadly, adverse events involved in potential lawsuits include deaths, strokes, heart attacks, as well as deblitating or disabling injuries from the effects of PRADAXA BLOOD.

FREE CASE EVALUATIONS ARE AVAILABLE FROM THE SPONSOR OF THIS SITE THROUGH USE OF THE CONTACT FORM BELOW.


QUE ES PRADAXA – INFORMACION EN ESPANOL

PRADAXA - INFORMACION EN ESPANOL - DABIGATRAN ETEXILATO.

EL MEDICAMENTO PRADAXA (DABIGATRAN ETEXILATO) – QUE ES?
INFORMACION SOBRE PRADAXA EN ESPANOL AQUI www.PRADAXABLOOD.com

PRADAXA (DABIGATRAN ETEXILATO) es un medicamento que disminuye el riesgo de formacion de coagulos de sangre. PRADAXA se utiliza para reducir el riesgo de obstruccion vascular sistemica por formacion de coagulos de sangre en pacientes con fibrilacion auricular or con latido del corazon anormal. El medicamento funciona bloqueando una sustancia del cuerpo y la formacion de coagulos de sangre.

Los siguientes son efectos adversos de PRADAXA:

  • Sangrado grave
  • Sangrado Largo o Excesivo
  • Debilidad Excepcional
  • Cansancio
  • Palidez
  • Mareo
  • Dolor De Cabez
  • Inflamacion Inexplicable
  • Sangrado de una articulacion
  • Sangrado en el lugar de entrada de una inyeccion
  • Sangrado en una incision quirurgica
  • Sangrado en el lugar de entrada de un cateter en una vena
  • Sangrado de la nariz
  • Sangrado en el estomago o intestino
  • Dolor en el ombligo o dolor del estomago
  • Ulcera gastro intestinal
  • Dificultad para respirar o respiracion siblante
  • Ataco Cardiaco
  • Formacion de hematomas
  • Disminucion de la proporcion de globulos rojos en la sangre
  • Aumento de enzimas hepaticos
  • Amarillenta o coloracion de la piel o del blanco de los ojos, causada por problemas hepaticos o sanguineos
  • Sangrado del pene/vagin o del trato urinario
  • Deposiciones frecuentes o movimientos intestinales liquidos
  • Indigestion
  • Sentire ganas de vomitar

Informe a su medico or farmaceutico si aprecia cualquier efecto adverso. Necessitas mas informacion sobre PRADAXA en espanol?

PRADAXA SANGRADO GRAVE, LARGO O EXCESIVO - INFORMACION EN ESPANOL.